SCHEMBL6532138

SCHEMBL6532138

O=C1Nc2ncccc2/C1=C/c1ccc2c(/C=C/c3cccnc3)n[nH]c2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 10/20 0.48
MAPT P10636 3/20 0.47
APP P05067 2/20 0.47
SNCA P37840 2/20 0.47
MAPK1 P28482 1/20 0.45
HTT P42858 1/20 0.45
CTRC Q99895 1/20 0.44
MAP3K11 Q16584 1/20 0.43
GSK3B P49841 1/20 0.41
CDK1 P06493 2/20 0.41
CDK4 P11802 2/20 0.41
CCNA2 P20248 2/20 0.41
CCND1 P24385 2/20 0.41
CDK2 P24941 2/20 0.41
CCND3 P30281 2/20 0.41
RAF1 P04049 1/20 0.40
NTRK1 P04629 1/20 0.40
TTK P33981 1/20 0.39
JAK3 P52333 1/20 0.38
KDR P35968 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6532142 1.00 CHEK1 (0.48) CHEK1MAPTAPPSNCAMAPK1
SCHEMBL12795347 1.00 CHEK1 (0.48) CHEK1MAPTAPPSNCAMAPK1
SCHEMBL6521731 0.90 CHEK1 (0.48) CHEK1MAPTAPPSNCACTRC
SCHEMBL6521736 0.90 CHEK1 (0.48) CHEK1MAPTAPPSNCACTRC
SCHEMBL602408 0.89 NTRK1 (0.50) CHEK1MAPTMAPK1HTTMAP3K11
SCHEMBL602406 0.89 NTRK1 (0.50) CHEK1MAPTMAPK1HTTMAP3K11
SCHEMBL15848833 0.89 NTRK1 (0.50) CHEK1MAPTMAPK1HTTMAP3K11
SCHEMBL602407 0.89 NTRK1 (0.50) CHEK1MAPTMAPK1HTTMAP3K11
SCHEMBL13654230 0.89 CHEK1 (0.45) CHEK1MAPTAPPSNCAMAPK1
SCHEMBL2546437 0.88 MAPT (0.62) CHEK1MAPTMAPK1HTTGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8765748-B2 Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer UNIVERSITY HEALTH NETWORK (CA) 2014-07-01 US disclosed
US-20110065702-A1 INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER UNIVERSITY HEALTH NETWORK 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065702-A1 INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER TNNI3K, ABL1, TK1 CHEK1 97/4885MAPT 964/4885APP 4843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.